Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018 Jul;56(4):268-291. \[[PubMed: 29980444](https://pubmed.ncbi.nlm.nih.gov/29980444)\] 45. Cheng L, Tan B, Yin Y, Wang S, Jia L, Warner G, Jia G, Jiang W. Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil. 2018 Oct;32(10):1299-1307. \[[PubMed: 29843523](https://pubmed.ncbi.nlm.nih.gov/29843523)\] 46. Tolle LB, Southern BD, Culver DA, Horowitz JC. Idiopathic pulmonary fibrosis: What primary care physicians need to know. Cleve Clin J Med. 2018 May;85(5):377-386. \[[PubMed: 29733782](https://pubmed.ncbi.nlm.nih.gov/29733782)\] 47. Harari S, Wells AU, Wuyts WA, Nathan SD, Kirchgaessler KU, Bengus M, Behr J. The 6-min walk test as a primary end-point in interstitial lung disease. Eur Respir Rev. 2022 Sep 30;31(165) \[[PMC free article: PMC9724818](/pmc/articles/PMC9724818/)\] \[[PubMed: 36002171](https://pubmed.ncbi.nlm.nih.gov/36002171)\] 48. Johannson KA, Pendharkar SR, Mathison K, Fell CD, Guenette JA, Kalluri M, Kolb M, Ryerson CJ. Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Ann Am Thorac Soc. 2017 Sep;14(9):1373-1377. \[[PubMed: 28644693](https://pubmed.ncbi.nlm.nih.gov/28644693)\] 49. Long-Term Oxygen Treatment Trial Research Group. Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016 Oct 27;375(17):1617-1627. \[[PMC free article: PMC5216457](/pmc/articles/PMC5216457/)\] \[[PubMed: 27783918](https://pubmed.ncbi.nlm.nih.gov/27783918)\] 50. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021 Feb 01;2(2):CD006322. \[[PMC free article: PMC8094410](/pmc/articles/PMC8094410/)\] \[[PubMed: 34559419](https://pubmed.ncbi.nlm.nih.gov/34559419)\] 51. Nolan CM, Polgar O, Schofield SJ, Patel S, Barker RE, Walsh JA, Ingram KA, George PM, Molyneaux PL, Maher TM, Man WD. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study. Chest. 2022 Mar;161(3):728-737. \[[PMC free article: PMC8941605](/pmc/articles/PMC8941605/)\] \[[PubMed: 34699771](https://pubmed.ncbi.nlm.nih.gov/34699771)\] 52. Marijic P, Schwarzkopf L, Maier W, Trudzinski F, Schwettmann L, Kreuter M. Effects of Influenza Vaccination in Patients with Interstitial Lung Diseases: An Epidemiological Claims Data Analysis. Ann Am Thorac Soc. 2022 Sep;19(9):1479-1488. \[[PMC free article: PMC9447394](/pmc/articles/PMC9447394/)\] \[[PubMed: 35312465](https://pubmed.ncbi.nlm.nih.gov/35312465)\] 53. Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968-77. \[[PMC free article: PMC3422642](/pmc/articles/PMC3422642/)\] \[[PubMed: 22607134](https://pubmed.ncbi.nlm.nih.gov/22607134)\] 54. Petnak T, Lertjitbanjong P, Thongprayoon